Would that be the top pick of 2020 ? Exelixis shows strong balance sheet plus the growth potential from further expansion. Stock Mover - Exelixis Further Expands Prostate Cancer Cohort in Phase 1b - Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 What do you guys think ?
Bouncing nicely off Fibonacci levels, looking to confirm bounce above 50%/$19 and the 200EMA. Will enter a long position with a short stop and will watch the 618 level.
I've been waiting on this trend line cross in Exelixis for quite a while now. It's been getting lots of analyst upgrades, and the valuation has been looking better and better. I actually bought some of this in anticipation of the break yesterday, so I'm in the green today. Exelixis's valuation got a 99/100 score from S&P Capital IQ. It has an attractive P/E of 8....
Monthly 50EMA support @17.40 We had a similar support and bounce in Nov-2018
EXEL price touched strong weekly support line and going up with trendline. possibly will go long. wait for 123 pattern for confirmation. I also watching this one.
Exelixis broke above a downward sloping trend line and also pushed above its 20-hour EMA. It's also above the Hull Moving Average and has uptrending RSI and MACD with plenty of room to run before it gets overbought. This is a lovely trend line break with a likely run to at least 21 before next downward oscillation. Exelixis reports earnings on July 31, with an 8%...
Nice volume on Friday, recent breakout after 2 months of consolidation, BBs expanding.
EXEL will bounce back with the markets starting from today.
Looks like will break out soon. Looking for 25.5, then maybe 28.
That is a company which reported just phenomenal earnings. EPS +400% revs +100% will hit 50 in few months. Technicals: broke 200 SMA and is in a uptrend for 2 years.
Rest all on chart. I am expecting next leg up towards 25 after this Dec-21 options expiry. Support range : 18~19.
Target is $21 in the short term if it does, if not it'll come back down to the $16-17 area. I see a downtrend continuing in my conjecture, but hey, it's investing. If I was great at this I would've retired by now. Trade safe!
Blow out sales and strong cash on recent quarter. Bottom formation is done and should bode well. Jan-14 : FDA approval for HCC due.
I'll take it at $11.50. It completed up to the 3.618 and then looks like it stalled. I took the first leg of money down to formulate the downwards pattern (yellow). I've got it hitting somewhere in the $11-12 range before we see a nice little bounce. I think it'll continue the downtrend more likely than not after that though. If you see a buyout, obviously...